ClinicalTrials.gg
Not yet recruitingNCT07459452Updated Mar 9, 2026

Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

A Phase 2 interventional study of JYB1904 and JYB1904 in Perennial Allergic Rhinitis, sponsored by Jemincare. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Jemincare · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of JYB1904 injection compared to placebo in patients with PAR.

02

Conditions studied

  • Perennial Allergic Rhinitis

Keywords

  • PAR
03

In context

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

This study's planned enrollment of 135 is close to the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.

Browse Rhinitis, Allergic, Perennial studies →

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult participants ≥18 years and ≤65 years of age at the time of signing the form (ICF).
  2. Physician-diagnosed PAR at screening, symptoms of allergic rhinitis present for a minimum of 2 years.
  3. Participants must have been on stable treatment with intranasal (INCS), with or without other background medications for at least four consecutive weeks before randomization, and rTNSS≥6 at screening.
  4. Within 1 year prior to screening or at screening, participants must have positive indoor allergen SPT and/or positive antigen-specific serum IgE to indoor allergens . Participants must have clinical symptoms associated with perennial allergen positivity (assessed by SPT) or positive serum antigen-specific IgE at study entry .
  5. A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.
  6. Participants who have concomitant asthma must use permitted regular asthma treatment during the study and have been stable in the 3 months prior to screening.
  7. Is willing and able to comply with daily eDiary.
  8. Participants must complete the eDiary during the baseline evaluation period (2 weeks prior to randomization) and meet the following criteria: (1) complete the eDiary for at least 4 days per week; and (2) rTNSS score ≥6 at randomization (average of Day-7 to Day-1).

Exclusion criteria

Exclusion Criteria:

  1. Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy.
  2. Have received treatment with any rescue medication or adjustment to background therapy medications during the baseline evaluation period.
  3. Prior intolerance or inadequate response to omalizumab.
  4. or to antihistamines or intranasal , or history of anaphylaxis.
  5. Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 2-week baseline evaluation period and the 24-week double-blind induction period.
  6. Anticipates significant changes in their daily environmental exposure during the 2-week baseline evaluation period and the 24-week double-blind induction period.
  7. Has a history of nasal polyps or nasal polyps present at screening, moderate-to-severe nasal septum deviation, or rhinitis secondary to other causes.
  8. Has a known history of recurrent acute or chronic sinusitis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    JYB1904 Q8W

    JYB1904 will be administered SC.

    Biological: JYB1904

  • Experimental
    JYB1904 Q12W

    300mg JYB1904 will be administered as a subcutaneous (SC) injection.

    Biological: JYB1904

  • Placebo comparator
    Placebo

    Placebo will be administered SC.

    Biological: Placebo+JYB1904

Interventions

  • BiologicalJYB1904

    Double-blind Induction Period: 150mg -450mg JYB1904 will be administered SC in Day1, Week 8 and Week 16. Open-label Treatment Period: 300mg JYB1904 will be administered SC every 12 weeks (Q12W) from Week 24 to Week 48.

  • BiologicalJYB1904

    Double-blind Induction Period: 300mg JYB1904 will be administered SC in Day1 and Week 12. Open-label Treatment Period: 300mg JYB1904 will be administered SC Q12W from Week 24 to Week 48.

  • BiologicalPlacebo+JYB1904

    Double-blind Induction Period: Placebo will be administered SC in Day1, Week 8, Week 12 and Week16. Open-label Treatment Period: 300mg JYB1904 will be administered SC Q12W from Week 24 to Week 48.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo)

    rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.

    Time frame: baseline, Week 8, Week 12

Other outcomes

  1. Change from Baseline in rTNSS at Each Visit

    rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.

    Time frame: up to Week 60

  2. Change from baseline in Rhinoconjunctivitis Quality of Life Questionnaire Standardized Version [RQLQ(S)] at each Visit

    The Rhinoconjunctivitis Quality of Life Questionnaire Standardized Version comprises 28 items that are grouped into 7 domains, each item was scored on a scale of 0 = Not troubled, 1 = Hardly troubled at all, 2 = Somewhat troubled, 3 = Moderately troubled, 4 = Quite a bit troubled, 5 = Very troubled, 6 = Extremely troubled. RQLQ(S) total mean scores will be calculated, with a range from 0 to 6. The higher the score was, the more serious the impact on the patient's life.

    Time frame: up to Week 60

  3. Number of days with controlled symptoms up to Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo)

    Controlled symptoms defined as rTNSS ≤4 with each individual item score ≤1. rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.

    Time frame: up to Week 8 or Week 12

  4. Number of days with controlled symptoms up to Week 24

    Time frame: up to Week 24

  5. Proportion of participants requiring rescue therapy at each visit up to Week 24

    Time frame: up to Week 24

  6. Proportion of participants with ≥30% reduction from baseline in rTNSS at each visit up to Week 24

    Time frame: up to Week 24

  7. Proportion of participants with ≥50% reduction from baseline in rTNSS at each visit up to Week 24

    Time frame: up to Week 24

  8. Change from Baseline in total ocular symptom score (TOSS) at each Visit

    TOSS is the sum of two symptom scores for itchy/red eyes and watery eyes, where each symptom is scored on a scale of 0 to 3. The higher the score was, the more severe the symptoms were.

    Time frame: up to Week 24

  9. Change from baseline in AR overall control Visual Analog Scale (VAS) at each visit

    The VAS, in which the participant rates the degree of bother caused by AR symptoms over the past 7 days on a 100 mm-long horizontal line, where 0 mm = no bother and 100 mm = extreme bother.

    Time frame: up to Week 24

  10. Adverse Events(AEs) and Serious Adverse Events (SAEs)

    Incidence and features of AEs and SAEs assessed by CTCAE v5.0, and related safety parameters analysis

    Time frame: Through study completion, an average of 72 weeks

  11. Pharmacokinetic (PK) profile of JYB1904 injection

    Serum concentration of JYB1904

    Time frame: Through study completion, an average of 72 weeks

  12. Pharmacodynamic (PD) profile of JYB1904 injection

    PD parameters: Changes in serum level of total and free IgE

    Time frame: Through study completion, an average of 72 weeks

  13. Immunogenicity of JYB1904 injection

    Immunogenicity parameters: Positive detection rate of anti-drug antibodies (ADA)/neutralizing ADA (Nab)

    Time frame: Through study completion, an average of 72 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Oct 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 9, 2026
StartEst.
Apr 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07459452
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Apr 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Mar 9, 2026

Study contacts

Zhiren Fang
Contact
fangzhiren@jeyoupharma.com
021-58306003
Luo Zhang
principal investigator · Beijing Tongren Hospital
Chengshuo Wang
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozureprubart

Start the discussion